Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery (EPO)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by University of Michigan.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Michigan
ClinicalTrials.gov Identifier:
NCT01393418
First received: July 12, 2011
Last updated: NA
Last verified: December 2010
History: No changes posted
  Purpose

The purpose of the study is to evaluate kidney biomarkers and determine if there is a correlation between erythropoietin levels and acute kidney injury after cardiac surgery. An early biomarker for kidney injury may be helpful in identifying, monitoring and managing patients at risk for kidney failure after cardiac surgery. To evaluate EPO's role as a predictor of poor renal function in the immediate post-bypass period we plan to compare EPO levels to NGAL.


Condition
Erythropoietin
Acute Kidney Injury
Renal Biomarker

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: EPO: A Renal Biomarker After Cardiac Surgery

Resource links provided by NLM:


Further study details as provided by University of Michigan:

Biospecimen Retention:   Samples Without DNA

Blood


Estimated Enrollment: 80
Study Start Date: November 2010
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Detailed Description:

Acute kidney injury (AKI) is a serious complication after cardiac surgery and cardio-pulmonary bypass. AKI is associated with high mortality.

Erythropoietin, a hormone produced by the kidneys, will be evaluated as a potential biomarker of kidney injury. Neutrophil gelatinase-associated lipocalin (NGAL)has been studied as a biomarker of kidney injury. Early kidney injury detection has been long sought and NGAL has been shown to be a promising biomarker. A troponinlike biomarker of AKI that is easily measured and capable of both early detection and risk stratification would represent an advancement in our ability to differentiate acute kidney injury from failure.

Investigating EPO as a biomarker may prove to have increased predictive value in the clinical care of cardiac surgery patients.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cardiac surgery patients.

Criteria

Inclusion Criteria:

  • Cardiac surgery with cardiopulmonary bypass with DHCA
  • Normal renal function or renal insufficiency-serum creatinine less than 2.5 mg/dL
  • Adult male and female patients 18 years and older

Exclusion Criteria:

  • VADS
  • Emergent cases
  • Prolonged hypoxemia before, during or after bypass
  • End stage renal disease
  • Patients receive erythropoietin receptor agonists
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01393418

Contacts
Contact: Theresa Shields, RN, BSN 734 232-5205 shieldt@med.umich.edu

Locations
United States, Michigan
University of Michigan Hospital Recruiting
Ann Arbor, Michigan, United States, 48109
Principal Investigator: Yasser El Kouatli, MD         
Sponsors and Collaborators
University of Michigan
Investigators
Principal Investigator: Yasser El Kouatli, MD Department of Anesthesiology, University of Michigan
  More Information

No publications provided

Responsible Party: Yasser El Kouatli/M.D., UmichiganHS
ClinicalTrials.gov Identifier: NCT01393418     History of Changes
Other Study ID Numbers: HUM41529
Study First Received: July 12, 2011
Last Updated: July 12, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of Michigan:
Erythropoietin
Cardiac Surgery
Renal Biomarker
Acute Kidney Injury
Hypothermic Circulatory Arrest

Additional relevant MeSH terms:
Acute Kidney Injury
Wounds and Injuries
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Epoetin Alfa
Hematinics
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 28, 2014